Елисеева С. В., Грачев С. В., Егорова Н. Д., Глезер М. Г., Асташкин Е. И. Влияние триметазидина на энергетическую активность митохондрий. Кардиоваскулярная терапия и профилактика. 2008;7(8):64-69.
1. Harpey C, Clauser P, Labrid C, et al. Trimetazidine, a cellular anti-ischemic agent. Cardiovasc Ddrug Rev 1989; 6: 292-312.
2. Renaud JF,. Internal pH, Na+ and Ca2+ regulation by trimetazidine during cardiac cell acidosis. Cardiovasc drugs Ther 1988; 1(6): 677-86.
3. Cruz C, Zaoui A, Ayoub S, et al. Alterations des myocytes isoles des ventricules de coeur de rat adulte: Protection par la trimetazidine. Concours Med 1987; 36(Suppl): 3470-5.
4. Tsimoyiannis EC, Moutesidou KJ, Moschos CM, et al. Trimetazidine for prevention of hepatic injury induced by ischemia and reperfusion in rats. Eur J Surg 1993; 159: 89-93.
5. Guarnieri C, Muscari C. Effectof trimetazidine on mitochondrial function and oxidative damage during reperfusion of ischemic hypertrophied rat myocardium. Pharmacology 1993; 46: 324-31.
6. Elimadi A, Settaf A, Morin D, et al. Trimetazidine counteracts the hepatic injury associated with ischemia-reperfusion by preserving mitochondrial function. J Pharmacol Exp Ther 1998;
7. Elimadi A, Morin D, Sapena R, et al. Comparison of the effects of cyclosporine A and trimetazidine on Ca2+-dependent mitochondrial swelling. Fundam Clin Pharmacol 1997; 11: 440-7.
8. Salducci MD, Chauvet-Monges AM, Tillement JP, et al. Trimetazidine reverses calcium accumulation and impairment of phosphorylation induced by cyclosporine A in isolated rat liver mitochondria. J Pharmacol Exp Ther 1996; 277: 417-22.
9. Tillement JP, Crevat A, Testa B, Le Ridant A. Pharmacological modulation of mitochondrial oxidative phosphorylation: inhibition by cyclosporine A, restoration by trimetazidine. Ann Pharm Fr 1996; 54(6): 268-71.
10. Morin D, Elimadi A, Sapena R, et al. Evidence for the existence of-trimetazidine binding sites involved in the regulation of the mitochondrial permeability transition pore. Brit J Pharmacol 1998; 123: 1385-94.
11. Morin D, Sapena R, Elimadi A, et al.-trimetazidine mitochondrial binding sites: regulation by cations, effect of trimetazidine derivatives and other agents and interaction with an endogenous substance. Brit J Pharmacol 2000; 130: 655-63.
12. Schneider WC, Hogeboom GH. Intracellular distribution of enzymes. J Biol Chem 1950; 183: 123.11.
13. Гублер Е.В., Генкин А.А. Применение непараметрических критериев статистики в медико-биологических исследованиях. Ленинград "Медицина" 1973; 141 с: 12.
14. Grynberg A, Demaison L. Fatty acid oxidation in the heart. J Cardiovasc Pharmacol 1996; 28(Suppl 1): Sl 1-7.
15. GrynbergA. Effectors offatty acid oxidation reduction: promising new anti-ischaemic agents. Curr Pharmaceutical Design 2005; 11(4): 489-509.
16. Essop MF, Opie LH. Metabolic therapy for heart failure. Eur Heart J 2004; 25: 1765-8.
17. Stanley WC, Marzilli M. Metabolic therapy in the treatment of ischaemic heart disease: the pharmacology of trimetazidine. Fundam Clin Pharmacol 2003; 17(2): 133-45.
18. Kantor PF, Lucien A, Kozak R, Lopaschuk GD. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res 2000; 86: 580-8.
19. Асташкин Е.И., Глезер М.Г. Фармакологическая регуляция обмена энергетических субстратов в кардиомиоцитах при патологических состояниях, связанных с ишемией. Кардиоваск тер профил 2006; 5(7): 112-23.
20. Tabbi-Anneni I, Lucien A, Grynberg A. Trimetazidine effect on phospholipid synthesis in ventricular myocytes: consequence in p-adrenergic dignaling. Fundam Clin Pharmacol 2003; 17: 51-9.
21. Argaud L, Gomez L, Gateau-Roesch O, et al. Trimetazidine inhibits mitochondrial permeability transition pore opening and prevents lethal ischemia-reperfusion injury. J Mol Cell Cardiol 2005; 39(6): 893-9.
22. Morillas Blasco PJ, Hernandiz Martinez A, Azorin Villena I, et al. Mitochondrial changes induced by trimetazidine in the myocardium. Med Sci Monit 2005; 11(6): BR 162-7.
23. Maridonneau-Parini I, Harpey C. Trimetazidine protects the human red blood cell against oxygen free radical damage. Cardiovasc Drugs Ther 1990; 4: 818-9.
